Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential immunotherapy and targeted therapy in BRAF-mutant metastatic melanoma
2014-004842-92Phase 2Completed
- Sponsor
- Fondazione Melanoma
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab, encorafenib and binimetinib in melanoma (3 arms), sponsored by Fondazione Melanoma. Primary endpoint: Overall survival. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-004842-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004842-92.